NanoCarrier to Give Presentations on NC-6004 (Nanoplatin®) Phase I Clinical Trial on at The 2008 AACR and ASCO Annual Meetings

NanoCarrier Co., Ltd. (headquartered in Kashiwa, Chiba; Ichiro Nakatomi, Ph.D., President and CEO) is conducting a Phase I clinical trial on micellar nanoparticles containing cisplatin derivatives (NC-6004, Nanoplatin®) in the United Kingdom. NanoCarrier today announced that its presentations on the trial will be given at the 2008 annual meetings of two American cancer associations.

This phase I clinical trial is being conducted in two centers in the United Kingdom in patients with progressive solid cancer. NC-6004 is intravenously administered once every three weeks according to the cisplatin regimen. It has been administered to a total of 17 patients with a dose range of 10 mg/m² to 120 mg/m². No toxicity that compels NanoCarrier to limit the dosage has been observed.

Investigators of this trial will make a presentation on the pharmacokinetics of platinum in plasma at the 2008 Annual Meeting of the American Association for Cancer Research (AACR) on April 13, 2008. A general overview on the Phase I trial will be given at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO) on June 1, 2008.

Presentation Title: Pharmacokinetics of NC-6004, a novel micellar formulation of cisplatin, in a Phase I trial
Authors: Melanie J Griffin, Julieann Sludden, Ruth Plummer, A Hilary Calvert, Richard H Wilson, R. Gallagher and M. M. Eatock, Y Matsumura, T Hayashi, T Shimizu, Alan V Boddy
Poster Session Category: Clinical Research 1
Abstract Number: 208
Presentation Date: Sunday, April 13, 2008

Presentation Title: Phase I and pharmacokinetic study of NC-6004, a new platinum entity of cisplatin-conjugated polymer forming micelles
Session Title: Developmental Therapeutics: Cytotoxic Chemotherapy
Abstract Number: 2573
Presentation Date: Sunday, June 1, 2008